COMMUNIQUÉS West-GlobeNewswire

ABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTP
12/12/2017
Additional results from the Phase III HERCULES study showed that treatment with caplacizumab resulted in: 38% relative reduction in the number of days of plasma exchange (PEX) 41% relative reduction in the volume of [...]
Corium to Join NASDAQ Biotechnology Index
12/12/2017
MENLO PARK, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI ), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty [...]
Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
12/12/2017
Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes (MDS) Presented Analyst and Investor Meeting and Webcast at 8:30 a.m. ET on December 19, 2017 MENLO PARK, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE [...]
Actinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual Meeting
12/12/2017
Higher cell death observed with Actinium-225 labeled daratumumab with up to ten-fold higher potency as compared to naked daratumuamb ARC of Daratumumab-Actinium-225 labeled with high yield, high stability and preserved [...]
Nature’s Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1
12/12/2017
CALGARY, Alberta, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX ) announced today that a recent Nature Scientific Reports has published a 12 page publication on BET ( [...]
Myriad’s BRACAnalysis CDx® Test Effectively Identified Metastatic Breast Cancer Patients with Improved Outcomes from Pfizer's PARP Inhibitor, Talazoparib
12/12/2017
SALT LAKE CITY, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, today announced that data from the EMBRACA trial showed Myriad’s [...]
Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting
12/12/2017
BERKELEY HEIGHTS, N.J., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC ) (NASDAQ: CYCCP ) "Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target [...]
Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease
12/12/2017
NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP ) (Tonix), a company that is developing innovative pharmaceutical and biological products to address public health challenges [...]
P. (Laxmin) Laxminarain Appointed to Microbot Medical’s Board of Directors
12/12/2017
HINGHAM, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT ), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today [...]
Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government
12/12/2017
GAITHERSBURG, Md., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) today announced that it has been awarded a contract by the Department of National Defence (DND) valued at approximately $8 [...]
MPX Enters Into Management & Purchase Option Agreements With LMS Wellness, Benefit LLC in Baltimore Maryland
12/12/2017
TORONTO, Dec. 12, 2017 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (the “ Company ” or “ MPX ”) (CSE:MPX) (OTC:MPXEF) today announced that the Company, through its indirect wholly-owned subsidiary, S8 Management, [...]
Zomedica Announces Achievement of Therapeutic Development Milestones
12/12/2017
ANN ARBOR, Mich., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V: ZOM ) (“Zomedica” or “Company”), a veterinary pharmaceutical and diagnostic company, today announced a [...]
Repros Therapeutics Inc.® Announces Acquisition by Allergan plc
12/12/2017
THE WOODLANDS, Texas, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (NASDAQ: RPRX ) (“Repros” or the “Company”) today announced that it has entered into a definitive agreement under which Allergan plc (“ [...]
Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israel’s Ministry of Health, Supporting Pivotal-Stage Studies
12/12/2017
Authorization is also under the provision of the Conformity Assessment and Acceptance of Industrial Products (CAA) agreement between Israel and the European Union (EU), which will serve to qualify Pluristem’s facilities [...]
Transactions in relation to share buyback program
12/12/2017
Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Genetic Technologies Provides Update on Strategic Review Initiative
12/12/2017
MELBOURNE, Australia, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ: GENE ) (“ Company ”), a molecular diagnostics company focused on cancer risk assessment, and provider of BREVAGen [...]
PsiOxus Therapeutics Receives $15 Million Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA
12/12/2017
OXFORD, United Kingdom, Dec. 12, 2017 (GLOBE NEWSWIRE) -- PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors [...]
Operational Update
12/12/2017
SYDNEY, Australia, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ: IMMP ) (Immutep or the Company), has provided an update on the Company’s two ongoing clinical trials with eftilagimod alpha (LAG- [...]
NEOVACS ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID IN TYPE 1 DIABETES
12/12/2017
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID IN TYPE 1 DIABETES Company intends to continue preclinical development in this indication in 2018 [...]

Pages